Celldex Therapeutics Company Profile (NASDAQ:CLDX)

About Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics logoCelldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CLDX
  • CUSIP: 15117B10
  • Web: www.celldextherapeutics.com
Capitalization:
  • Market Cap: $302.88 million
  • Outstanding Shares: 128,341,000
Average Prices:
  • 50 Day Moving Avg: $2.45
  • 200 Day Moving Avg: $2.99
  • 52 Week Range: $2.20 - $5.02
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.36
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $9.46 million
  • Price / Sales: 32.02
  • Book Value: $1.82 per share
  • Price / Book: 1.30
Profitability:
  • EBIDTA: ($115,220,000.00)
  • Net Margins: -1,318.94%
  • Return on Equity: -51.87%
  • Return on Assets: -37.19%
Debt:
  • Current Ratio: 5.56%
  • Quick Ratio: 5.56%
Misc:
  • Average Volume: 1.78 million shs.
  • Beta: 2.75
  • Short Ratio: 5.37
 

Frequently Asked Questions for Celldex Therapeutics (NASDAQ:CLDX)

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.05. The company earned $3.83 million during the quarter, compared to analyst estimates of $1.21 million. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. The firm's revenue was up 175.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.32) earnings per share. View Celldex Therapeutics' Earnings History.

Where is Celldex Therapeutics' stock going? Where will Celldex Therapeutics' stock price be in 2017?

8 brokerages have issued 12-month target prices for Celldex Therapeutics' shares. Their predictions range from $3.00 to $16.00. On average, they expect Celldex Therapeutics' stock price to reach $8.08 in the next year. View Analyst Ratings for Celldex Therapeutics.

What are analysts saying about Celldex Therapeutics stock?

Here are some recent quotes from research analysts about Celldex Therapeutics stock:

  • 1. According to Zacks Investment Research, "Celldex’s efforts to build its immuno-oncology pipeline are impressive. Its lead pipeline candidate, glembatumumab vedotin, is in mid-stage development for different types of cancer.  Apart from glembatumumab vedotin, Celldex has several promising candidates in its pipeline, including varlilumab. We are also encouraged by Celldex’s partnership agreements with big players like Bristol-Myers. Meanwhile, the recent Kolltan acquisition adds some interesting candidates to the company’s pipeline. However, with no approved product in its portfolio, Celldex has to depend entirely on product development and licensing agreements, contracts and grants for revenues. We are also concerned about the early- to mid-stage nature of its pipeline. Estimates have remained mostly stable lately ahead of the Q2 results. Celldex has a positive record of earnings surprises in the recent quarters. " (7/17/2017)
  • 2. Cowen and Company analysts commented, "At ASCO updates on varli and glemba were provided." (6/6/2017)
  • 3. Jefferies Group LLC analysts commented, "The PIII METRIC trial evaluating glemba has observed recent patient acceleration due to new EU sites and driving a potential enrollment completion by Sept 2017. Based on this timeline, data could be available in 2Q18, and we remain less optimistic on the success of the trial. In '17, we should receive data from PI portion of varli+nivo." (3/15/2017)

Who are some of Celldex Therapeutics' key competitors?

Who are Celldex Therapeutics' key executives?

Celldex Therapeutics' management team includes the folowing people:

  • Larry Ellberger, Independent Chairman of the Board
  • Anthony S. Marucci, President, Chief Executive Officer, Director
  • Sam Martin, Chief Financial Officer, Senior Vice President
  • Tibor Keler Ph.D., Executive Vice President and Chief Scientific Officer
  • Thomas Andrew Davis M.D., Executive Vice President and Chief Medical Officer
  • Sarah Cavanaugh, Senior Vice President - Corporate Affairs and Administration
  • Elizabeth Crowley, Senior Vice President, Chief Product Development Officer
  • Theresa M. LaVallee Ph.D., Senior Vice President - Regulatory and Precision Medicine
  • Ronald A. Pepin Ph.D., Senior Vice President and Chief Business Officer
  • Richard Wright Ph.D., Senior Vice President, Chief Commercial Officer`

Who owns Celldex Therapeutics stock?

Celldex Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.81%), FMR LLC (7.80%), KLP Enterprises LLC (5.49%), Meditor Group Ltd (4.64%), Northern Trust Corp (1.62%) and State Street Corp (1.50%). Company insiders that own Celldex Therapeutics stock include Avery W Catlin, Larry Ellberger and Tibor Keler. View Institutional Ownership Trends for Celldex Therapeutics.

Who sold Celldex Therapeutics stock? Who is selling Celldex Therapeutics stock?

Celldex Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, State Street Corp, Federated Investors Inc. PA, Frontier Capital Management Co. LLC, Goldman Sachs Group Inc., New York State Common Retirement Fund, Russell Investments Group Ltd. and Numeric Investors LLC. View Insider Buying and Selling for Celldex Therapeutics.

Who bought Celldex Therapeutics stock? Who is buying Celldex Therapeutics stock?

Celldex Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Meditor Group Ltd, Vanguard Group Inc., Ameriprise Financial Inc., Dimensional Fund Advisors LP, Northern Trust Corp, Teachers Advisors LLC, Virtu KCG Holdings LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Celldex Therapeutics stock in the last two years include Larry Ellberger and Tibor Keler. View Insider Buying and Selling for Celldex Therapeutics.

How do I buy Celldex Therapeutics stock?

Shares of Celldex Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celldex Therapeutics' stock price today?

One share of Celldex Therapeutics stock can currently be purchased for approximately $2.36.


MarketBeat Community Rating for Celldex Therapeutics (NASDAQ CLDX)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  299 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  427
MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Celldex Therapeutics (NASDAQ:CLDX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $8.08 (242.51% upside)

Analysts' Ratings History for Celldex Therapeutics (NASDAQ:CLDX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/9/2017HC WainwrightSet Price TargetBuy$10.00HighView Rating Details
6/29/2017AegisReiterated RatingBuyMediumView Rating Details
6/6/2017Cowen and CompanyReiterated RatingBuyHighView Rating Details
5/11/2017Jefferies Group LLCReiterated RatingHold$4.00 -> $3.50HighView Rating Details
11/10/2016Roth CapitalReiterated RatingBuy$7.00N/AView Rating Details
11/8/2016WedbushReiterated RatingNeutral$3.00N/AView Rating Details
11/8/2016Cantor FitzgeraldReiterated RatingBuy$9.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$16.00N/AView Rating Details
3/7/2016Leerink SwannDowngradeOutperform -> Market Perform$30.00 -> $4.00N/AView Rating Details
3/7/2016Oppenheimer Holdings, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
3/7/2016GuggenheimDowngradeBuy -> NeutralN/AView Rating Details
(Data available from 8/17/2015 forward)

Earnings

Earnings History for Celldex Therapeutics (NASDAQ:CLDX)
Earnings by Quarter for Celldex Therapeutics (NASDAQ:CLDX)
Earnings History by Quarter for Celldex Therapeutics (NASDAQ CLDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.28)($0.23)$1.21 million$3.83 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.29)($0.28)$0.57 million$1.53 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.34)($0.30)$1.10 million$1.87 millionViewListenView Earnings Details
11/7/2016Q3 2016($0.33)($0.29)$1.09 million$2.20 millionViewN/AView Earnings Details
8/8/2016Q2($0.34)($0.32)$0.96 million$1.39 millionViewListenView Earnings Details
5/5/2016Q1 16($0.35)($0.35)$1.06 million$1.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.35)($0.33)$0.80 million$1.80 millionViewListenView Earnings Details
11/5/2015Q3($0.35)($0.32)$1.02 million$1.03 millionViewN/AView Earnings Details
8/10/2015Q215($0.34)($0.33)$0.51 million$2.18 millionViewListenView Earnings Details
4/29/2015Q115($0.36)($0.33)$0.52 million$0.49 millionViewN/AView Earnings Details
2/24/2015Q314($0.35)($0.36)$0.49 million$1.50 millionViewN/AView Earnings Details
11/4/2014Q3($0.33)($0.31)$0.43 million$1.10 millionViewN/AView Earnings Details
8/6/2014Q214($0.31)($0.32)$0.38 million$0.60 millionViewN/AView Earnings Details
5/1/2014Q1 2014($0.26)($0.33)$0.34 million$0.40 millionViewN/AView Earnings Details
3/3/2014Q413($0.28)($0.27)$0.27 million$0.62 millionViewN/AView Earnings Details
11/5/2013Q313($0.24)($0.29)$0.09 million$1.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.22)($0.24)$1.57 million$0.97 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.22)($0.23)$2.65 million$2.41 millionViewN/AView Earnings Details
3/7/2013Q4 2012($0.25)($0.27)$2.45 million$3.65 millionViewN/AView Earnings Details
11/1/2012Q312($0.24)($0.25)$2.07 million$3.11 millionViewN/AView Earnings Details
8/10/2012($0.25)($0.23)ViewN/AView Earnings Details
5/3/2012($0.25)($0.27)ViewN/AView Earnings Details
3/7/2012($0.26)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celldex Therapeutics (NASDAQ:CLDX)
2017 EPS Consensus Estimate: ($1.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.30)($0.26)($0.28)
Q2 20173($0.27)($0.23)($0.26)
Q3 20173($0.28)($0.20)($0.24)
Q4 20173($0.29)($0.20)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celldex Therapeutics (NASDAQ:CLDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Celldex Therapeutics (NASDAQ:CLDX)
Insider Ownership Percentage: 4.10%
Institutional Ownership Percentage: 63.88%
Insider Trades by Quarter for Celldex Therapeutics (NASDAQ:CLDX)
Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)
Insider Trades by Quarter for Celldex Therapeutics (NASDAQ:CLDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/2/2016Tibor KelerVPBuy3,000$3.32$9,960.00View SEC Filing  
11/23/2015Avery W. CatlinCFOSell25,000$18.00$450,000.00View SEC Filing  
8/25/2015Larry EllbergerDirectorBuy5,000$14.00$70,000.00View SEC Filing  
8/20/2015Larry EllbergerDirectorBuy5,000$15.00$75,000.00View SEC Filing  
8/18/2015Larry EllbergerDirectorBuy5,000$15.95$79,750.00View SEC Filing  
8/13/2015Anthony S MarucciCEOBuy5,800$16.81$97,498.00View SEC Filing  
8/13/2015Larry EllbergerDirectorBuy5,000$16.59$82,950.00View SEC Filing  
6/15/2015Avery W CatlinCFOSell25,000$24.59$614,750.00View SEC Filing  
12/6/2013Avery CatlinCFOSell183,333$24.50$4,491,658.50View SEC Filing  
12/6/2013Larry EllbergerDirectorSell17,728$24.50$434,336.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Celldex Therapeutics (NASDAQ:CLDX)
Latest Headlines for Celldex Therapeutics (NASDAQ:CLDX)
Source:
DateHeadline
finance.yahoo.com logoCelldex Therapeutics, Inc. – Value Analysis (NASDAQ:CLDX) : August 17, 2017
finance.yahoo.com - August 16 at 10:44 PM
americanbankingnews.com logo-$0.25 Earnings Per Share Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter
www.americanbankingnews.com - August 16 at 9:42 AM
finance.yahoo.com logoCelldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : August 14, 2017
finance.yahoo.com - August 14 at 10:40 PM
americanbankingnews.com logoFY2017 EPS Estimates for Celldex Therapeutics, Inc. (NASDAQ:CLDX) Reduced by Analyst
www.americanbankingnews.com - August 11 at 11:18 AM
finance.yahoo.com logoEdited Transcript of CLDX earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 6:29 PM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS
www.americanbankingnews.com - August 9 at 10:48 PM
seekingalpha.com logoCelldex Therapeutics' (CLDX) CEO Anthony Marucci on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 9 at 5:26 PM
nasdaq.com logoCelldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up - Nasdaq
www.nasdaq.com - August 9 at 5:26 PM
fool.com logoCelldex Therapeutics, Inc. Finishes Second Quarter With Plenty of Cash and Clinical Momentum
www.fool.com - August 9 at 8:15 AM
rttnews.com logoEARNINGS SUMMARY: Details of Celldex Therapeutics Inc. Q2 Earnings Report
www.rttnews.com - August 8 at 10:03 PM
finance.yahoo.com logoCelldex reports 2Q loss
finance.yahoo.com - August 8 at 10:03 PM
globenewswire.com logoCelldex Reports Second Quarter 2017 Results - GlobeNewswire (press release)
globenewswire.com - August 8 at 5:00 PM
finance.yahoo.com logoCelldex Reports Second Quarter 2017 Results
finance.yahoo.com - August 8 at 5:00 PM
finance.yahoo.com logoCelldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : August 4, 2017
finance.yahoo.com - August 4 at 5:32 PM
americanbankingnews.com logoCritical Comparison: Celldex Therapeutics (NASDAQ:CLDX) and Compugen (CGEN)
www.americanbankingnews.com - August 3 at 8:40 AM
nasdaq.com logoWhat's in the Cards for Celldex (CLDX) this Earnings Season? - Nasdaq
www.nasdaq.com - August 2 at 6:00 PM
feeds.benzinga.com logoCelldex to Report Second Quarter 2017 Financial Results and Host Corporate Update Call
feeds.benzinga.com - August 2 at 12:38 PM
streetinsider.com logoUPDATE: HC Wainwright Assumes Celldex Therapeutics (CLDX) at Buy - StreetInsider.com
www.streetinsider.com - August 1 at 5:56 PM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:16 AM
americanbankingnews.com logo$490,000.00 in Sales Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter
www.americanbankingnews.com - July 31 at 7:33 AM
americanbankingnews.com logo-$0.26 EPS Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter
www.americanbankingnews.com - July 29 at 7:21 AM
americanbankingnews.com logoCelldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - July 25 at 4:51 PM
finance.yahoo.com logoBetter Buy: Celldex Therapeutics, Inc. vs. Juno Therapeutics
finance.yahoo.com - July 19 at 6:32 AM
americanbankingnews.com logoZacks Investment Research Lowers Celldex Therapeutics, Inc. (NASDAQ:CLDX) to Sell
www.americanbankingnews.com - July 17 at 3:26 PM
americanbankingnews.com logoCelldex Therapeutics, Inc. (NASDAQ:CLDX) Short Interest Down 16.0% in June
www.americanbankingnews.com - July 15 at 7:04 AM
fool.com logoDown 14.8%: Is Celldex Therapeutics Stock an Incredible Bargain? - Motley Fool
www.fool.com - July 14 at 7:17 PM
finance.yahoo.com logoDown 14.8%: Is Celldex Therapeutics Stock an Incredible Bargain?
finance.yahoo.com - July 14 at 7:17 PM
americanbankingnews.com logoCelldex Therapeutics, Inc. (NASDAQ:CLDX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - July 11 at 9:38 PM
seekingalpha.com logoCelldex: Can It Succeed Just Once? - Seeking Alpha
seekingalpha.com - July 7 at 4:36 AM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Expected to Announce Quarterly Sales of $490,000.00
www.americanbankingnews.com - July 6 at 9:24 AM
americanbankingnews.com logo Brokerages Expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) Will Post Earnings of -$0.26 Per Share
www.americanbankingnews.com - July 4 at 10:28 PM
americanbankingnews.com logoCelldex Therapeutics, Inc. (NASDAQ:CLDX) Rating Reiterated by Aegis
www.americanbankingnews.com - July 1 at 8:04 AM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 30 at 9:11 AM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Short Interest Down 9.1% in June
www.americanbankingnews.com - June 29 at 7:25 AM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - June 27 at 5:50 PM
finance.yahoo.com logoCelldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team
finance.yahoo.com - June 16 at 5:05 PM
finance.yahoo.com logoWhy Is Celldex (CLDX) Down 27% Since the Last Earnings Report?
finance.yahoo.com - June 13 at 12:39 PM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Short Interest Update
www.americanbankingnews.com - June 12 at 7:18 AM
americanbankingnews.com logoZacks: Analysts Expect Celldex Therapeutics, Inc. (CLDX) to Post -$0.26 Earnings Per Share
www.americanbankingnews.com - June 8 at 10:18 PM
globenewswire.com logoCelldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ASCO Annual Meeting - GlobeNewswire (press release)
globenewswire.com - June 7 at 2:46 PM
fool.com logoHere's Why Celldex Therapeutics, Inc. Fell Today - Motley Fool
www.fool.com - June 7 at 2:46 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Celldex Therapeutics and Pandora Media
finance.yahoo.com - June 7 at 2:46 PM
finance.yahoo.com logoHere's Why Celldex Therapeutics, Inc. Fell Today
finance.yahoo.com - June 6 at 9:37 PM
americanbankingnews.com logoCowen and Company Reiterates "Buy" Rating for Celldex Therapeutics, Inc. (CLDX)
www.americanbankingnews.com - June 6 at 5:32 PM
finance.yahoo.com logoCelldex Therapeutics to Participate in the Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 6 at 4:34 PM
streetinsider.com logoCelldex (CLDX) Presents Phase 1 Study of Varlilumab and Opdivo at ASCO
www.streetinsider.com - June 5 at 9:17 PM
finance.yahoo.com logoHere's What Shaved 14% Off Celldex Therapeutics, Inc.'s Stock Price in May
finance.yahoo.com - June 5 at 9:17 PM
finance.yahoo.com logoCelldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ASCO Annual Meeting
finance.yahoo.com - June 5 at 9:17 PM
feeds.benzinga.com logoCelldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ASCO Annual Meeting
feeds.benzinga.com - June 5 at 5:07 PM
fool.com logoHere's What Shaved 14% Off Celldex Therapeutics, Inc.'s Stock Price in May
www.fool.com - June 5 at 4:50 PM

Social

Chart

Celldex Therapeutics (CLDX) Chart for Thursday, August, 17, 2017

This page was last updated on 8/17/2017 by MarketBeat.com Staff